Mitsubishi UFJ Trust & Banking Corp Trims Position in Humana Inc. (NYSE:HUM)

Mitsubishi UFJ Trust & Banking Corp lowered its stake in shares of Humana Inc. (NYSE:HUM) by 19.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 63,594 shares of the insurance provider’s stock after selling 15,688 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Humana were worth $16,134,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in HUM. Transcend Capital Advisors LLC grew its stake in shares of Humana by 399.7% in the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock valued at $924,000 after purchasing an additional 2,914 shares during the last quarter. FNY Investment Advisers LLC lifted its holdings in shares of Humana by 6,647.5% during the fourth quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock worth $6,916,000 after purchasing an additional 26,856 shares during the period. Retirement Systems of Alabama increased its stake in Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after buying an additional 192,801 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Humana by 7.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock valued at $244,811,000 after buying an additional 65,735 shares during the period. Finally, PDT Partners LLC raised its position in Humana by 190.0% during the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock worth $1,286,000 after buying an additional 2,660 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

NYSE HUM opened at $263.95 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market cap of $31.86 billion, a price-to-earnings ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The business has a fifty day moving average of $270.14 and a 200-day moving average of $274.38.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.34%. Humana’s payout ratio is currently 35.58%.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.37% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on HUM shares. Barclays boosted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Piper Sandler boosted their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Morgan Stanley reduced their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Finally, Truist Financial boosted their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Eighteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.